-- 根据FactSet调查的分析师报告，Corbus Pharmaceuticals Holdings Inc (CRBP) 的平均评级为“买入”，平均目标价为41.67美元。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）
Related Articles
Australia
Starbucks Sustains Sales Momentum in April on Better Execution, Morgan Stanley Says
Starbucks (SBUX) sustained its sales momentum in April, driven by ongoing innovation and better execution despite a dynamic macro landscape, Morgan Stanley said in a Wednesday research report.The company's solid Q2 earnings beat was driven by transaction strength with margin beat partly linked to accounting in the China deal, but North America margins continue to face pressure, analysts wrote.The brokerage raised its Q3 and Q4 comp forecast to 5.7% and 4.7%, respectively. For Q3, it expects EPS of $0.63 and $0.67 for Q4. For the full-year 2026, Morgan Stanley now expects EPS of $2.37 from $2.27 earlier.Operations, staffing, innovation, marketing, and improving the asset base appear to be driving compounding benefits alongside the impacts from cost actions, according to the note.The brokerage said it reiterated its overweight rating on the stock and boosted its price target to $110 per share from $105 earlier.Price: $104.81, Change: $+7.53, Percent Change: +7.74%
$SBUX
Australia
Rothschild & Co Redburn Adjusts GE Vernova Price Target to $1,200 From $1,100, Maintains Buy Rating
GE Vernova (GEV) has an average rating of overweight and mean price target of $1,190.40, according to analysts polled by FactSet.Price: $1068.97, Change: $-19.97, Percent Change: -1.83%
$GEV
Australia
Wells Fargo Adjusts Price Target on PACCAR to $125 From $119, Maintains Equalweight Rating
PACCAR Inc (PCAR) has an average rating of hold and mean price target of $129.70, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $119.82, Change: $+0.21, Percent Change: +0.18%
$PCAR